Display options
Cite
Flagg EW, Datta SD, Saraiya M, et al. Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009. Cancer Causes Control. 2014;25(5):571-81doi: 10.1007/s10552-014-0362-x.
Flagg, E. W., Datta, S. D., Saraiya, M., Unger, E. R., Peters, E., Cole, L., Chen, V. W., Tucker, T., Byrne, M. J., Copeland, G., Silva, W., Watson, M., & Weinstock, H. (2014). Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009. Cancer causes & control : CCC, 25(5), 571-81. https://doi.org/10.1007/s10552-014-0362-x
Flagg, Elaine W, et al. "Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009." Cancer causes & control : CCC vol. 25,5 (2014): 571-81. doi: https://doi.org/10.1007/s10552-014-0362-x
Flagg EW, Datta SD, Saraiya M, Unger ER, Peters E, Cole L, Chen VW, Tucker T, Byrne MJ, Copeland G, Silva W, Watson M, Weinstock H. Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009. Cancer Causes Control. 2014 May;25(5):571-81. doi: 10.1007/s10552-014-0362-x. Epub 2014 Feb 28. PMID: 24578200; PMCID: PMC6921482.
Copy Download .nbib Format: NLM
Share it on

Cancer Causes Control. 2014 May;25(5):571-81. doi: 10.1007/s10552-014-0362-x. Epub 2014 Feb 28.

Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009.

Cancer causes & control : CCC

Elaine W Flagg, S Deblina Datta, Mona Saraiya, Elizabeth R Unger, Edward Peters, Lauren Cole, Vivien W Chen, Thomas Tucker, Mary Jane Byrne, Glenn Copeland, Won Silva, Meg Watson, Hillard Weinstock

Affiliations

  1. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MS E-02, Atlanta, GA, 30333, USA, [email protected].

PMID: 24578200 PMCID: PMC6921482 DOI: 10.1007/s10552-014-0362-x

Abstract

PURPOSE: The USA has a well-established network of central cancer registries (CCRs) that collect data using standardized definitions and protocols to provide population-based estimates of cancer incidence. The addition of cervical cancer precursors in select CCR operations would facilitate future studies measuring the population-level impact of human papillomavirus (HPV) vaccine. To assess the feasibility of collecting data on cervical cancer precursors, we conducted a multi-site surveillance study in three state-wide CCRs, to obtain annual case counts and compare rates of precursor lesions to those for invasive cervical cancer.

METHODS: We developed standardized methods for case identification, data collection and transmission, training and quality assurance, while allowing for registry-specific strategies to accomplish surveillance objectives. We then conducted population-based surveillance for precancerous cervical lesions in three states using the protocols.

RESULTS: We identified 5,718 cases of cervical cancer precursors during 2009. Age-adjusted incidence of cervical cancer precursors was 77 (Kentucky), 60 (Michigan), and 54 (Louisiana) per 100,000 women. Highest rates were observed in those aged 20-29 years: 274 (Kentucky), 202 (Michigan), and 196 (Louisiana) per 100,000. The variable with the most missing data was race/ethnicity, which was missing for 13 % of cases in Kentucky, 18 % in Michigan, and 1 % in Louisiana. Overall rates of cervical cancer precursors were over sixfold higher than invasive cervical cancer rates [rate ratios: 8.6 (Kentucky), 8.3 (Michigan), and 6.2 (Louisiana)].

CONCLUSIONS: Incorporating surveillance of cervical cancer precursors using existing CCR infrastructure is feasible and results in collection of population-based incidence data. Standardized collection of these data in high-quality registry systems will be useful in future activities monitoring the impact of HPV vaccination across states. As a result of this study, ongoing surveillance of these lesions has now been conducted in four CCRs since 2010.

References

  1. Lancet Oncol. 2008 May;9(5):425-34 - PubMed
  2. Int J Cancer. 2013 Jan 1;132(1):198-207 - PubMed
  3. CA Cancer J Clin. 2012 May-Jun;62(3):147-72 - PubMed
  4. Vaccine. 2010 Jul 5;28(30):4731-7 - PubMed
  5. MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9 - PubMed
  6. JAMA. 2001 Mar 21;285(11):1500-5 - PubMed
  7. Cancer. 2008 Nov 15;113(10 Suppl):2946-54 - PubMed
  8. Expert Rev Vaccines. 2008 May;7(4):437-56 - PubMed
  9. MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 - PubMed
  10. J Low Genit Tract Dis. 2012 Jul;16(3):205-42 - PubMed
  11. Sex Health. 2010 Sep;7(3):325-7 - PubMed
  12. J Low Genit Tract Dis. 2013 Oct;17(4):397-403 - PubMed
  13. Sex Health. 2010 Sep;7(3):310-9 - PubMed
  14. J Registry Manag. 2010 Winter;37(4):152-5 - PubMed
  15. Lancet. 2001 Jun 9;357(9271):1831-6 - PubMed
  16. JAMA. 2001 Jun 20;285(23):2995-3002 - PubMed
  17. Cancer. 2008 Nov 15;113(10 Suppl):3047-57 - PubMed
  18. J Infect Dis. 2005 Mar 1;191(5):731-8 - PubMed
  19. Vaccine. 2011 Jan 29;29(5):878-85 - PubMed
  20. Cancer Causes Control. 2012 Feb;23(2):281-8 - PubMed
  21. J Natl Cancer Inst. 1990 Jun 20;82(12):988-91 - PubMed
  22. J Low Genit Tract Dis. 2012 Oct;16(4):471-9 - PubMed
  23. J Pathol. 2006 Jan;208(2):152-64 - PubMed
  24. JAMA. 2002 Apr 24;287(16):2114-9 - PubMed
  25. J Clin Virol. 2005 Mar;32 Suppl 1:S16-24 - PubMed
  26. Am J Clin Pathol. 2009 Jul;132(1):125-32 - PubMed

MeSH terms

Publication Types

Grant support